MedTrace Logo

Prospective Multicenter Registry Study of Multiple System Atrophy in China

NCT07644013 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 214

Last updated 2026-06-12

No results posted yet for this study

Summary

Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited.

This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.

Conditions

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Zhaoxia Wang, MD · Department of Neurology, Peking University First Hospital

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2029-12-31
Completion
2030-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07644013 on ClinicalTrials.gov